{rfName}
Re

Indexed in

License and use

Citations

Altmetrics

Analysis of institutional authors

Fontanals, SCorresponding AuthorEsteve, AAuthorGonzalez, AAuthorMesia, RAuthorClopes, AAuthor
Share
Publications
>
Article

Real-world treatment outcomes of immune checkpoint inhibitors used off-label in oncology: A comprehensive cancer institution experience

Publicated to:Pharmacol Res Perspect. 12 (1): e1167- - 2024-02-01 12(1), DOI: 10.1002/prp2.1167

Authors: Fontanals, S; Esteve, A; González, A; Ibáñez, C; Mesía, R; Clopés, A

Affiliations

Blanquerna Ramon Llull Univ, Catalan Inst Oncol ICO Hospitalet, Inst Invest Biomed Bellvitge IDIBELL, ICO,Sch Hlth Sci,Pharm Dept - Author
Blanquerna Ramon Llull Univ, Catalan Inst Oncol ICO Hospitalet, Sch Hlth Sci, ICO,Pharm Dept - Author
Catalan Inst Oncol ICO, Pharm Dept - Author
Germans Trias & Pujol Res Inst IGTP, Badalona Appl Res Grp Oncol B ARGO, Catalan Inst Oncol ICO, Med Oncol Dept,ICO - Author
Germans Trias & Pujol Res Inst IGTP, Catalan Inst Oncol ICO, Med Oncol Dept, ICO,ICO Badalona,Res Management Unit UGR,Appl Res - Author
See more

Abstract

Keywords
AdultAgedArticleAtezolizumabCancerCancer immunotherapyCancer stagingCardiotoxicityCemiplimabDecision makingDisease exacerbationDrug withdrawalDurvalumabEcog performance statusEvent free survivalFemaleHead and neck cancerHumanHumansImmune checkpoint inhibitorImmune checkpoint inhibitorsKaplan meier methodLiver dysfunctionMaleMalignant neoplasmMedical oncologyMelanomaMetastasisMiddle agedNeoplasmNeoplasmsNivolumabNon small cell lung cancerOff label drug useOff-label useOncologyOverall survivalPembrolizumabProgrammed death 1 ligand 1Programmed death 1 receptorSolid tumorSurvivalTreatment durationTreatment outcomeTreatment outcomes

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Pharmacol Res Perspect due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Pharmacology, Toxicology and Pharmaceutics (Miscellaneous).

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-15:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 5.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 5 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 6.95.
  • The number of mentions on the social network X (formerly Twitter): 12 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (FONTANALS MARTINEZ, SANDRA) and Last Author (Clopes Estela, Ana Maria).

the author responsible for correspondence tasks has been FONTANALS MARTINEZ, SANDRA.